Pulmonary arterial hypertension associated to connective tissue diseases

Abstract

Pulmonary arterial hypertension is a well-known complication of connective tissue diseases such as systemic sclerosis, systemic lupus erythematosus, mixed connective tissue diseases, and to a lesser extent, rheumatoid arthritis, dermatopolymyositis and primary Sjögren’s syndrome. In these patients, pulmonary hypertension may occur in association with left heart disease, interstitial fibrosis or as a result of a isolated pulmonary arteriopathy. The incidence of pulmonary arterial hypertension in the limited form of systemic sclerosis is about 10%. The pathophysiologic mechanisms leading to pulmonary arterial hypertension remain unknown. Symptoms and clinical presentation are very similar to idiopathic pulmonary arterial hypertension but mortality was confirmed to be higher. Echocardiography is the reference investigation for the detection of pulmonary arterial hypertension but the results should be confirmed by right heart catheterization. Treatment appears more complex as compared to idiopathic pulmonary arterial hypertension. Intravenous epoprostenol therapy has been shown to be effective in a special trail. Also, the endothelin receptor antagonists bosentan and sitaxentan, the phosphodyesterase-type-5 sildenafil and subcutaneous treprostinil have shown favourable results.

Keywords

connective tissue diseases pulmonary arterial hypertension pulmonary arteriopathy systemic sclerosis

Get full access to this article

View all access options for this article.

References

Hatano S , Strasser T. Primary pulmonary hypertension. World Health Organization 1975, WHO: Geneva , 1975.

Simonneau G , Galie N , Rubin L et al. Clinical classification of pulmonary arterial hypertension . J Am Coll Cardiol 2004; 43: S5-S12 .

D’Alonzo GE , Barst RJ , Ayres SM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry . Ann Intern Med 1991; 115: 343-349 .

Rubin LJ. Primary pulmonary hypertension . N Engl J Med 1997; 336: 111-117 .

Galie N , Manes A , Uguccioni L et al. Primary pulmonary hypertension: insights into pathogenesis from epidemiology . Chest 1998; 114(3 Suppl): 184S-194S .

Pietra GG , Capron F , Stewart S et al. Pathologic assessment of vasculopathies in pulmonary hypertension . J Am Coll Cardiol 2004; 43(12 Suppl 1): S25-S32 .

Humbert M , Morrell N , Archer S et al. Cellular and molecular pathobiology of pulmonary arterial hypertension . J Am Coll Cardiol 2004: 43(12 Suppl 1): S13-S24 .

Humbert M , Chaouat A , Bertocchi M , Sitbon M , Simonneau G. ItinerAIR-HTAP: a French national prospective registry of pulmonary arterial hypertension . Am J Resp Crit Care Med 2004; 169: A169-A169 .

Budhiraja R , Tuder RM , Hassoun PM. Endothelial dysfunction in pulmonary hypertension . Circulation 2004; 109: 159-165 .

10.

Mukerjee D , St George D , Coleiro B et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach . Ann Rheum Dis 2003; 62: 1088-1093 .

11.

Pan TL , Thumboo J , Boey ML. Primary and secondary pulmonary hypertension in systemic lupus erythematosus . Lupus 2000; 9: 338-342 .

12.

Sanchez O , Humbert M , Sitbon O , Simonneau G. Treatment of pulmonary hypertension secondary to connective tissue diseases . Thorax 1999; 54: 273-277 .

13.

Fagan KA , Badesch DB. Pulmonary hypertension associated with connective tissue disease . Prog Cardiovasc Dis 2002; 45: 225-234 .

14.

MacGregor AJ , Canavan R , Knight C et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival . Rheumatology 2001; 40: 453-459 .

15.

Yoshida S , Katayama M. Pulmonary hypertension in patients with connective tissue diseases . Nippon Rinsho 2001; 59: 1164-1167 .

16.

Rich S , Dantzker DR , Ayres SM et al. Primary pulmonary hypertension. A national prospective study . Ann Intern Med 1987; 107: 216-223 .

17.

Filep JG , Bodolay E , Sipka S , Gyimesi E , Csipo I , Szegedi G. Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective tissue disease . Circulation 1995; 92: 2969-2974 .

18.

McQuillan BM , Picard MH , Leavitt M , Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects . Circulation 2001; 104: 2797-2802 .

19.

Sitbon O , Humbert M , Ioos V et al. Who benefits from long-term calcium-channel blocker therapy in primary pulmonary hypertension ? Am J Resp Crit Care Med 2003; 167: (abstract 440).

20.

Galie N , Torbicki A , Barst R et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology . Eur Heart J 2004; 25: 2243-2278 .

21.

Rubin LJ , Badesch DB , Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension . N Engl J Med 2002; 346: 896-903 .

22.

Barst RJ , Langleben D , Frost A et al. Sitaxsentan therapy for pulmonary arterial hypertension . Am J Respir Crit Care Med 2004; 169: 441-447 .

23.

Oudiz R , Schilz R , Barst R et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease . Chest 2004; 126: 420-427 .

24.

Badesch DB , Tapson VF , McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial (see comments) . Ann Intern Med 2000; 132: 425-434 .

25.

Humbert M , Sanchez O , Fartoukh M et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study . Eur Respir J 1999; 13: 1351-1356 .